CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis

Cutaneous leishmaniasis (CL) affects the lives of 0.7–1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first line of therapy for CL, however the treatment is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Thacker, Seth G, McWilliams, Ian L., Bonnet, Beatrice, Halie, Lydia, Beaucage, Serge, Rachuri, Swaksha, Dey, Ranadhir, Duncan, Robert, Modabber, Farrokh, Robinson, Stephen, Bilbe, Graeme, Arana, Byron, Verthelyi, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075640/
https://www.ncbi.nlm.nih.gov/pubmed/32109251
http://dx.doi.org/10.1371/journal.pntd.0008050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075640/
https://www.ncbi.nlm.nih.gov/pubmed/32109251
http://dx.doi.org/10.1371/journal.pntd.0008050

Ejemplares similares